Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024:46:e20233095.
doi: 10.47626/1516-4446-2023-3095. Epub 2023 Sep 17.

Prevalence of antidepressant use in Brazil: a systematic review with meta-analysis

Affiliations
Meta-Analysis

Prevalence of antidepressant use in Brazil: a systematic review with meta-analysis

Gustavo Magno Baldin Tiguman et al. Braz J Psychiatry. 2024.

Abstract

Objectives: To estimate the prevalence of antidepressant use in Brazil.

Methods: We conducted a systematic review with searches in MEDLINE, Embase, Scopus, LILACS, and SciELO up to May 2023. Two researchers independently selected studies, extracted data, and assessed the methodological quality. We pooled the prevalence of antidepressant use using meta-analyses of proportions (Freeman-Tukey transformation) and estimated heterogeneity by the I2 statistic. OR meta-analyses of antidepressant use by sex were calculated (men as reference) and between-study variation was explored by meta-regressions.

Results: Out of 3,299 records retrieved, 23 studies published in 28 reports were included, with a total of 75,061 participants. The overall prevalence of antidepressant use was 4.0% (95%CI 2.7-5.6%; /² = 98.5%). Use of antidepressants in the previous 3 days was higher in women (12.0%; 95%CI 9.5-15.1%; /² = 0%) than men (4.6%; 95%CI 3.1-6.8%; /² = 0%) (p < 0.001; OR = 2.82; 95%CI 1.72-4.62). Gender differences were particularly higher for antidepressant use in the previous year (women: 2.3%; 95%CI 1.6-3.1; /² = 37.6% vs. men: 0.5%; 95%CI 0.2-1.0%; /² = 0%, p < 0.001; OR = 4.18; 95%CI 2.10-8.30). Between-study variation in the overall prevalence of antidepressant use significantly increased with mean participant age (p = 0.035; residual /² = 0%; regression coefficient = 0.003).

Conclusion: Four out of every 100 Brazilians used antidepressants in this 3-decade assessment. Use increased with age and was more prevalent in women compared to men.

Registration number: PROSPERO CRD42022345332.

Keywords: Antidepressive agents; drug utilization; mental health; prevalence; systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

Figures

Figure 1
Figure 1. Flow diagram of study selection and inclusion.
Figure 2
Figure 2. Prevalence of antidepressant use (%) and 95%CI according to the recall period adopted.
Figure 3
Figure 3. Variability of the overall prevalence of antidepressant use by mean age, recall period, and start and end years of studies.

Similar articles

Cited by

References

    1. GBD 2019 Mental Disorders Collaborators Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9:137. - PMC - PubMed
    1. Freeman M. Investing for population mental health in low and middle income countries-where and why? Int J Ment Health Syst. 2022;16:38. - PMC - PubMed
    1. Rathod S, Pinninti N, Irfan M, Gorczynski P, Rathod P, Gega L, et al. Mental health service provision in low- and middle-income countries. Health Serv Insights. 2017;10:1178632917694350. - PMC - PubMed
    1. Lopes CS. How is Brazilian’s mental health? The importance of birth cohorts for better understanding the problem. Cad Saude Publica. 2020;36:e00005020. - PubMed
    1. Tiguman GMB, Silva MT, Galvao TF. Prevalence of depressive and anxiety symptoms and their relationship with life-threatening events, tobacco dependence and hazardous alcohol drinking: a population-based study in the Brazilian Amazon. J Affect Disord. 2022;298:224–31. - PubMed

Substances